AZ Hopes Coupling GLP-1 Bydureon and SGLT-2 Forxiga Is Paradigm Shift
AstraZeneca hopes positive results from its DURATION-8 trial combining its GLP-1 drug Bydureon and SGLT2 product Forxiga for the first time will spur use – and sales – for each, and open the way for an additional line of defense for type 2 diabetes patients before they are moved onto insulin.
You may also be interested in...
Novo Nordisk's investigational GLP-1 agonist semaglutide promises to elevate the Danish group's product offering and market position, its CSO says in an interview with Scrip.
New data from Novo Nordisk supporting its GLP-1 agonist will fortify the firm's new drug applications, strengthen its position in price negotiations and boost its chances of reimbursement.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.